Ken Keller is President and CEO of Daiichi Sankyo, Inc. He is also the head of the Global Oncology Business and serves as a member of Daiichi Sankyo’s Global Management Committee. Mr. Keller joined Daiichi Sankyo Inc. in 2014.

Through his work with Daiichi Sankyo, and prior to that with Amgen Inc., Mr. Keller has more than 30 years of experience in the pharmaceutical industry. He has led multi-billion dollar businesses in the U.S. and Europe.

Through leadership roles in multiple markets, across cultures and within different healthcare systems, Mr. Keller has successfully launched numerous biologic products in therapeutic areas ranging from oncology to bone health to nephrology to inflammatory diseases, transformed businesses, and delivered sustainable revenue and profit growth.

Since joining Daiichi Sankyo, Inc., Mr. Keller has shifted the structure of the U.S. business to focus on launching multiple oncology therapeutics in the coming years. He is known for his inclusive leadership approach and his passion for bringing innovative drugs to patients in need.

Mr. Keller is a member of the PhRMA Board of Directors and was previously a board member of the Association of the British Pharmaceutical Industry. He holds a Bachelor of Science degree in Business from Saint John's University and a Master of Business Administration degree from Loyola Marymount University.